{
 "drug": "Nilutamide Tablet",
 "asOf": "2026-08-25",
 "status": "discontinuing",
 "since": "12/01/2025",
 "dayN": 267,
 "cat": "Oncology",
 "companies": [
  "Advanz Pharma (US) Corp."
 ],
 "reasons": [],
 "records": [
  {
   "discontinued_date": "12/01/2025",
   "update_type": "New",
   "initial_posting_date": "12/01/2025",
   "package_ndc": "59212-111-14",
   "generic_name": "Nilutamide Tablet",
   "contact_info": "847-283-7921",
   "related_info": "Product to expire in March 2026; Discontinuation of the manufacture of the drug",
   "update_date": "12/01/2025",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Tablet",
   "presentation": "Nilandron, Tablet, 150 mg (NDC 59212-111-14)",
   "company_name": "Advanz Pharma (US) Corp.",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "12/01/2025",
   "update_type": "New",
   "initial_posting_date": "12/01/2025",
   "package_ndc": "66993-212-38",
   "generic_name": "Nilutamide Tablet",
   "contact_info": "847-283-7921",
   "related_info": "Product to expire in March 2026; Discontinuation of the manufacture of the drug",
   "update_date": "12/01/2025",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Tablet",
   "presentation": "Nilandron, Tablet, 150 mg (NDC 66993-212-38)",
   "company_name": "Advanz Pharma (US) Corp.",
   "status": "To Be Discontinued"
  }
 ]
}